A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults

. 2003 Dec 01 ; 21 (32) : 4650-4.

Jazyk angličtina Země Nizozemsko Médium print

Typ dokumentu klinické zkoušky, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid14585671

Vivaxim is a combined hepatitis A/typhoid fever vaccine (HA/Vi) licensed for vaccination of travellers, but long-term protection against hepatitis A requires two immunisations at least 6 months apart. A randomised, controlled study was performed in 116 healthy adults primed with hepatitis A vaccine (Avaxim) to compare immune responses to HA/Vi and Avaxim given as booster doses 6 months later. Both vaccines elicited marked booster responses achieving antibody geometric mean titres (GMTs) of 4576 and 3760 mIU/ml in the HA/Vi and Avaxim groups, respectively. Although twice as frequent in the HA/Vi group, local reactions (mostly pain) were mainly mild and transient, probably reflecting the larger volume injected (1ml). Vivaxim offers a convenient means of administering both HA and typhoid fever vaccines in subjects already primed for hepatitis A.

Citace poskytuje Crossref.org

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...